Free Trial

DiaMedica Therapeutics (DMAC) News Today

DiaMedica Therapeutics logo
$4.06 +0.01 (+0.25%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$4.06 0.00 (-0.12%)
As of 05/23/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

DMAC Latest News

DiaMedica Therapeutics Inc. stock logo
Research Analysts Offer Predictions for DMAC FY2025 Earnings
DiaMedica Therapeutics Inc. (NASDAQ:DMAC - Free Report) - Stock analysts at HC Wainwright boosted their FY2025 earnings per share (EPS) estimates for shares of DiaMedica Therapeutics in a research report issued on Thursday, May 15th. HC Wainwright analyst M. Caufield now forecasts that the compan
Equities Analysts Offer Predictions for DMAC FY2025 Earnings
Equities Analysts Offer Predictions for DMAC FY2029 Earnings
DiaMedica Therapeutics Inc. stock logo
DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Shares Acquired by Susquehanna International Group LLP
Susquehanna International Group LLP lifted its holdings in DiaMedica Therapeutics Inc. (NASDAQ:DMAC - Free Report) by 269.5% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 374,845 shares of the company'
DiaMedica Therapeutics Inc. stock logo
DiaMedica Therapeutics (DMAC) Projected to Post Earnings on Wednesday
DiaMedica Therapeutics (NASDAQ:DMAC) will be releasing its Q1 2025 earnings before the market opens on Wednesday, May 14. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-14-diamedica-therapeutics-inc-stock/)
DiaMedica Therapeutics Inc. stock logo
683 Capital Management LLC Buys New Shares in DiaMedica Therapeutics Inc. (NASDAQ:DMAC)
683 Capital Management LLC bought a new position in shares of DiaMedica Therapeutics Inc. (NASDAQ:DMAC - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund bought 76,116 shares of the company's stock, valued at approximately $413,000. 683 Capital Ma
DiaMedica Therapeutics Inc. stock logo
DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Short Interest Update
DiaMedica Therapeutics Inc. (NASDAQ:DMAC - Get Free Report) was the target of a significant growth in short interest during the month of March. As of March 31st, there was short interest totalling 366,400 shares, a growth of 38.7% from the March 15th total of 264,200 shares. Approximately 0.9% of the company's shares are short sold. Based on an average trading volume of 90,200 shares, the days-to-cover ratio is presently 4.1 days.
DiaMedica Therapeutics Inc. stock logo
Equities Analysts Set Expectations for DMAC Q1 Earnings
DiaMedica Therapeutics Inc. (NASDAQ:DMAC - Free Report) - Stock analysts at HC Wainwright issued their Q1 2025 EPS estimates for DiaMedica Therapeutics in a research report issued to clients and investors on Wednesday, March 19th. HC Wainwright analyst M. Caufield expects that the company will po
DiaMedica Therapeutics Inc. stock logo
DiaMedica Therapeutics (NASDAQ:DMAC) Price Target Raised to $10.00 at HC Wainwright
HC Wainwright raised their price target on DiaMedica Therapeutics from $7.00 to $10.00 and gave the company a "buy" rating in a research report on Wednesday.
Diamedica Therapeutics (DMAC) Gets a Buy from Lake Street
DiaMedica Therapeutics Inc. stock logo
DiaMedica Therapeutics (NASDAQ:DMAC) Announces Earnings Results
DiaMedica Therapeutics (NASDAQ:DMAC - Get Free Report) issued its quarterly earnings results on Monday. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.01).
DiaMedica Therapeutics reports FY24 EPS (60c), consensus (59c)
DiaMedica Therapeutics Inc. stock logo
DiaMedica Therapeutics (DMAC) to Release Quarterly Earnings on Tuesday
DiaMedica Therapeutics (NASDAQ:DMAC) will be releasing earnings before the market opens on Tuesday, March 18, Financial Modeling Prep reports.
DiaMedica Therapeutics Inc. stock logo
Short Interest in DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Grows By 21.1%
DiaMedica Therapeutics Inc. (NASDAQ:DMAC - Get Free Report) was the recipient of a large growth in short interest in February. As of February 15th, there was short interest totalling 232,300 shares, a growth of 21.1% from the January 31st total of 191,900 shares. Based on an average trading volume of 113,800 shares, the short-interest ratio is presently 2.0 days.
DiaMedica Therapeutics publishes DM199 data in Stroke
Craig-Hallum Sticks to Their Buy Rating for Diamedica Therapeutics (DMAC)
DiaMedica Therapeutics Inc. stock logo
Short Interest in DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Drops By 8.4%
DiaMedica Therapeutics Inc. (NASDAQ:DMAC - Get Free Report) was the target of a significant drop in short interest during the month of January. As of January 31st, there was short interest totalling 191,900 shares, a drop of 8.4% from the January 15th total of 209,500 shares. Based on an average daily volume of 103,200 shares, the short-interest ratio is currently 1.9 days.
DiaMedica Therapeutics Inc. stock logo
DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Sees Significant Increase in Short Interest
DiaMedica Therapeutics Inc. (NASDAQ:DMAC - Get Free Report) was the target of a large growth in short interest in January. As of January 15th, there was short interest totalling 222,800 shares, a growth of 14.5% from the December 31st total of 194,600 shares. Based on an average daily trading volume, of 93,700 shares, the days-to-cover ratio is presently 2.4 days.
DiaMedica Therapeutics Inc. stock logo
DiaMedica Therapeutics (NASDAQ:DMAC) Shares Down 1.5% - Time to Sell?
DiaMedica Therapeutics (NASDAQ:DMAC) Shares Down 1.5% - Here's What Happened
DiaMedica Therapeutics Inc. stock logo
DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Short Interest Up 28.4% in December
DiaMedica Therapeutics Inc. (NASDAQ:DMAC - Get Free Report) was the recipient of a large growth in short interest in December. As of December 15th, there was short interest totalling 194,600 shares, a growth of 28.4% from the November 30th total of 151,500 shares. Based on an average trading volume of 87,500 shares, the days-to-cover ratio is presently 2.2 days.
DiaMedica Therapeutics Inc. stock logo
Short Interest in DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Declines By 12.2%
DiaMedica Therapeutics Inc. (NASDAQ:DMAC - Get Free Report) was the recipient of a significant drop in short interest in November. As of November 30th, there was short interest totalling 151,500 shares, a drop of 12.2% from the November 15th total of 172,500 shares. Based on an average daily trading volume, of 83,100 shares, the short-interest ratio is presently 1.8 days.
DiaMedica Therapeutics Inc. stock logo
DiaMedica Therapeutics (NASDAQ:DMAC) Trading 0.6% Higher - Should You Buy?
DiaMedica Therapeutics (NASDAQ:DMAC) Trading Up 0.6% - Should You Buy?
DiaMedica Therapeutics Inc. stock logo
DiaMedica Therapeutics (NASDAQ:DMAC) Given Buy Rating at HC Wainwright
HC Wainwright reiterated a "buy" rating and issued a $7.00 price target on shares of DiaMedica Therapeutics in a report on Friday.
DiaMedica Therapeutics doses first patient in Phase 2 DM199 trial
Preview: DiaMedica Therapeutics's Earnings
Get DiaMedica Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for DMAC and its competitors with MarketBeat's FREE daily newsletter.

DMAC Media Mentions By Week

DMAC Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

DMAC
News Sentiment

0.77

0.73

Average
Medical
News Sentiment

DMAC News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

DMAC Articles
This Week

8

1

DMAC Articles
Average Week

Get DiaMedica Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for DMAC and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:DMAC) was last updated on 5/24/2025 by MarketBeat.com Staff
From Our Partners